Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Open Access
- 2 August 2022
- journal article
- review article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 26, 471-494
Abstract
No abstract availableKeywords
This publication has 190 references indexed in Scilit:
- ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical TrialsCells, 2012
- Self-complementary AAVs Induce More Potent Transgene Product-specific Immune Responses Compared to a Single-stranded GenomeMolecular Therapy, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Capsid-specific T-cell Responses to Natural Infections With Adeno-associated Viruses in Humans Differ From Those of Nonhuman PrimatesMolecular Therapy, 2011
- A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8Molecular Therapy, 2011
- Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid ProteinsMolecular Therapy, 2011
- Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical ApplicationMolecular Therapy, 2010
- Dystrophin Immunity in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2010
- Proteasome Inhibitors Decrease AAV2 Capsid derived Peptide Epitope Presentation on MHC Class I Following TransductionMolecular Therapy, 2010
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage CommitmentImmunity, 2009